Navigation Links
SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
Date:10/23/2008

DUBLIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today presented data on MP-470, its lead product candidate, and four additional posters, at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. MP-470, an orally bio-available multi-targeted tyrosine kinase inhibitor, showed encouraging tumor regression results in the first two arms (paclitaxel/carboplatin and carboplatin/etoposide) of its current Phase 1b clinical trial examining MP-470 combined with five standard of care (SOC) anticancer treatments.

"We are extremely pleased to report a series of important clinical and scientific advances achieved by our Company," said James S. Manuso, Ph.D., SuperGen's President and Chief Executive Officer. "In addition to MP-470's progress in the clinic, before year-end, we expect to enter SGI-1776, our PIM kinase inhibitor, into Phase 1 clinical trials. This will be our second novel drug in clinical development."

In a poster presentation (Abstract #403) entitled, "Clinical responses of highly refractory solid tumor patients to oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens. Preliminary report from a multi-institutional phase 1b clinical trial," Dr. A. Tolcher, Director of Clinical Research at START (South Texas Accelerated Research Therapeutics) in San Antonio, Texas, highlighted data showing tumor regression in four patients in the two arms, indicating that MP-470 may sensitize/re-sensitize tumors to the anticancer effects of SOC regimens of DNA-damaging agents. Of note, MP-470 did not increase the types or severity of adverse events. However, a primary endpoint of the trial - determining the maximum tolerated dose of MP-470 co-administered with SOC regimens - has not been reached and dose escalation continues.

"These compelling results strengthen the rationale for combining MP-470 with DNA-damaging agents due to MP-470's purported ability to suppress the Rad51 DNA repair mechanism, which is important in various malignancies," said Dr. Gregory Berk, SuperGen's Chief Medical Officer. "We look forward to presenting updated results on MP-470 in combination with these platinum doublets, as well as the other three standard of care arms of the trial in the future."

Earlier this year, U.S. Food and Drug Administration granted orphan drug designation for MP-470 in the treatment of glioblastoma multiforme (GBM) after non-clinical studies showed more than two-fold effect of increased cell death when used synergistically with ionizing radiation. Orphan drug designation for GBM, an often fatal form of brain cancer, can entitle SuperGen to seven years of market exclusivity. SuperGen's lead product candidate has also shown promise in preclinical testing across a wide spectrum of cancers, including non-small cell lung cancer.

Furthermore, SuperGen presented four additional posters at the Symposium that reviewed clinical and non-clinical advances of the compounds MP-470, SGI-1776 and SGI-1252. These include:

Abstract 332: In vivo activity of SGI-1776, an orally active PIM kinase

inhibitor

Abstract 426: Effects of food on the single-dose pharmacokinetics of oral

MP-470 capsules

Abstract 480: MP-470, a novel multi-targeted tyrosine kinase inhibitor

targeting Rad51 is not toxic to human primary marrow stem cells at

clinically relevant concentrations

Abstract 571: Modulation of JAK2 signaling pathways in vitro and in vivo

Copies of the 20th EORTC-NCI-AACR Symposium poster presentations will be available in the pipeline section of SuperGen's Web site http://www.supergen.com.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipate," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts:

SuperGen, Inc. Dorland Global Public Relations

Timothy L. Enns Michael Beckerich (Media)

SVP, Corporate Communications Tel: (212) 677-7632

& Business Development mbeckerich@dorland.com

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
2. Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud
3. First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
4. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
5. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
6. Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
7. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
8. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
9. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
10. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
11. Job-related stress: NIST demonstrates fatigue effects in silicon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join ... clinical research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, ...
(Date:1/18/2017)... -- HUYA Bioscience International, (HUYA), the leader in accelerating the ... innovations, announced today a strategic collaboration agreement with the ... to as CAS Innovation). The collaboration will focus on ... at CAS to meet the medical needs of patients ... company to have recognized China,s ...
(Date:1/17/2017)... ... 17, 2017 , ... MS Technologies™ and Bayer have received ... Performance System will combine industry-leading genetics with a double herbicide-tolerant trait that will ... Bean herbicide. The Balance™ GT Soybean Performance System will benefit soybean growers by ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
Breaking Biology Technology:
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
(Date:12/16/2016)... 2016   IdentyTechSolutions America LLC , a ... solutions and a cutting-edge manufacturer of software and ... offering seamless, integrated solutions that comprise IDT biometric ... solutions provide IdentyTech,s customers with combined physical identification ... crime and theft. "We are proud ...
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):